🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 74 (from laksa036)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa074.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://www.sinovac.com/en-us/news/release/page/5\')), getAhrefsUnparsedNoserviceFromURL(\'https://www.sinovac.com/en-us/news/release/page/5\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/5","crawl_time":1776170692,"first_indexed_time":1740516100,"http_code":200,"src_unparsed":"com,sinovac!www,\/en-us\/news\/release\/page\/5 s443","src_root_hash":"13504451120479472074","history_drop_reason":null,"meta_title":"Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases-page5","meta_descriptions":["SINOVAC: Supply Vaccines to Eliminate Human Diseases"],"attrs_boilerpipe_text":"Press Releases\nALL YEAR\nAll\nYEAR 2026\nYEAR 2025\nYEAR 2024\nYEAR 2023\nYEAR 2022\nYEAR 2021\nYEAR 2020\nYEAR 2019\nYEAR 2018\nYEAR 2017\nYEAR 2016\nYEAR 2015\nYEAR 2014\nYEAR 2013\nYEAR 2012\nYEAR 2011\nYEAR 2010\nYEAR 2009\nYEAR 2008\nYEAR 2007\nYEAR 2006\nYEAR 2005\n2022\/08\/20\nSinovac Beijing's QC Laboratory Accredited By CNAS\nAugust 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that the Qual\n2022\/08\/15\nSINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong\nAugust 3, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat\n2022\/07\/19\nSINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile\nJuly 19, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli\n2022\/07\/14\nSINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil\nJuly 14, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va\n2022\/07\/04\nSINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China\nHONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C\n2022\/06\/25\nSINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa\nSinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R\n2022\/06\/02\nSINOVAC Polio Vaccine Prequalified by WHO\nBEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal\n2022\/05\/26\nChilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population\nOn May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report \"AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent\n2022\/05\/11\nSINOVAC Honored \"MITRA BUMN GLOBAL CHAMPION 2022\" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine\nMay 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the \"MITRA BUMN GLOBAL CHAMPION 2022\" awa\n2022\/04\/30\nSINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F\nBEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S.\n2022\/04\/26\nChina NMPA approved SINOVAC Omicron-specific vaccine for clinical trial\nApril 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de\n2022\/04\/17\nSINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong\nApril 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie\n2022\/03\/23\nThree doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave\nA study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of\n2022\/03\/16\nChile Research: CoronaVac\n®\nis safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old\nThe inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and\n2022\/03\/16\nChile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak\nOn Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen\n2022\/03\/16\nLatest Real-World Data Show Two-shots of CoronaVac\n®\nProvides 74.5% Protection Against COVID-19 For Children and Adolescents\nReal-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi\n2022\/03\/04\nBrazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided\nDuring the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p\n2022\/02\/25\nCUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony\nRepresented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C\n2022\/02\/18\nCUHK and SINOVAC join in hands in building P3 laboratory\nDeveloping the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework\n2021\/12\/31\nSINOVAC Reports Unaudited First Half of 2021 Financial Results\nBEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results\nPrevious page\n1...\n2\n3\n4\n5\n6\n7\n8\n...26\nNext page\nGo to No.","attrs_markdown":"[![Logo Keywords](https:\/\/www.sinovac.com\/upload\/202212\/1672113330.svg)](https:\/\/www.sinovac.com\/en-us \"SINOVAC: Supply Vaccines to Eliminate Human Diseases\")\n\n- [Company](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Company\")\n - [SINOVAC at Glance](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/about#met_148)\n - [Our History](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/about#met_438)\n - [Social Responsibilities](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/about#met_433)\n- [Innovation](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Innovation\")\n - [Platform](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_167)\n - [Pipeline](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_168)\n - [Scientific Achievements](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_169)\n - [Partners](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_170)\n - [— Research Institute](https:\/\/www.sinovac.com\/en-us\/research\/partners\/Research_Institute)\n - [— Universities](https:\/\/www.sinovac.com\/en-us\/research\/partners\/Universities)\n - [— Medical Institutions](https:\/\/www.sinovac.com\/en-us\/research\/partners\/Medical_institutions)\n - [— Companies](https:\/\/www.sinovac.com\/en-us\/research\/partners\/companies)\n- [Products](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Products\")\n - [Vaccines](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products#met_440)\n - [International Business](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products#met_165)\n - [Quality Management System](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products#met_173)\n - [Product Consultation](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products\/consultation)\n - [Adverse Event Report](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/aefi)\n\n- [News](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"News\")\n - [Press Releases](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/news#met_154)\n - [Updates and Statements](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/news#met_155)\n - [Media Asset Library](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/news#met_434)\n- [Investors](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Investors\")\n - [Corporate Governance](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/Investors\/corporate_governance\/Board_of_Directors)\n - [Financial Reports](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports)\n - [SEC Filings](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings)\n- [Careers](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Careers\")\n - [Our Talent](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/careers\/talents)\n- [中文](\"链接关键词\") [EN](\"链接关键词\")\n- [Contact Us](https:\/\/www.sinovac.com\/en-us\/contact)\n\n- [Company](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:;)\n - [SINOVAC at Glance](https:\/\/www.sinovac.com\/en-us\/about\/at_glance_cn)\n - [Our History](https:\/\/www.sinovac.com\/en-us\/about\/Our_History)\n - [Social Responsibilities](https:\/\/www.sinovac.com\/en-us\/about\/Responsibilities)\n- [News](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:;)\n - [Press Releases](https:\/\/www.sinovac.com\/en-us\/news\/release)\n - [Updates and Statements](https:\/\/www.sinovac.com\/en-us\/news\/coverage)\n - [Media Asset Library](https:\/\/www.sinovac.com\/en-us\/news\/Media)\n - [— Logo](https:\/\/www.sinovac.com\/en-us\/download2\/class-435)\n - [— Vaccines](https:\/\/www.sinovac.com\/en-us\/download2\/class-436)\n- [Innovation](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:;)\n - [Platform](https:\/\/www.sinovac.com\/en-us\/research\/platform)\n - [Pipeline](https:\/\/www.sinovac.com\/en-us\/research\/pipeline)\n - [Scientific Achievements](https:\/\/www.sinovac.com\/en-us\/research\/achievements)\n - [Partners](https:\/\/www.sinovac.com\/en-us\/research\/partners)\n - [— Research Institute](https:\/\/www.sinovac.com\/en-us\/research\/partners\/Research_Institute)\n - [— Universities](https:\/\/www.sinovac.com\/en-us\/research\/partners\/Universities)\n - [— Medical Institutions](https:\/\/www.sinovac.com\/en-us\/research\/partners\/Medical_institutions)\n - [— Companies](https:\/\/www.sinovac.com\/en-us\/research\/partners\/companies)\n- [Products](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:;)\n - [Vaccines](https:\/\/www.sinovac.com\/en-us\/products\/portfolio)\n - [International Business](https:\/\/www.sinovac.com\/en-us\/products\/international-business)\n - [Quality Management System](https:\/\/www.sinovac.com\/en-us\/products\/publicity)\n - [Product Consultation](https:\/\/www.sinovac.com\/en-us\/products\/consultation)\n - [Adverse Event Report](https:\/\/www.sinovac.com\/en-us\/aefi)\n- [Investors](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:;)\n - [Corporate Governance](https:\/\/www.sinovac.com\/en-us\/Investors\/corporate_governance\/Board_of_Directors)\n - [— Board of Directors](https:\/\/www.sinovac.com\/en-us\/Investors\/corporate_governance\/Board_of_Directors)\n - [— Board Committees & Charters](https:\/\/www.sinovac.com\/en-us\/Investors\/corporate_governance\/Board_Committees_and_Charters)\n - [Financial Reports](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports)\n - [— YEAR 2024](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2023)\n - [— YEAR 2023](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2024)\n - [— YEAR 2021](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2021)\n - [— YEAR 2022](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2022)\n - [— YEAR 2020](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2020)\n - [— YEAR 2019](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2019)\n - [— YEAR 2018](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2018)\n - [— YEAR 2017](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2017)\n - [— YEAR 2016](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2016)\n - [— YEAR 2015](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2015)\n - [— YEAR 2014](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2014)\n - [— YEAR 2013](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2013)\n - [— YEAR 2012](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2012)\n - [— YEAR 2011](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2011)\n - [— YEAR 2010](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2010)\n - [— YEAR 2009](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2009)\n - [— YEAR 2008](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2008)\n - [— YEAR 2007](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2007)\n - [— YEAR 2006](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2006)\n - [— YEAR 2005](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2005)\n - [— YEAR 2004](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2004)\n - [— YEAR 2003](https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports\/financial_reports_2003)\n - [SEC Filings](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings)\n - [— YEAR 2025](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/sec_filings2025)\n - [— YEAR 2024](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC)\n - [— YEAR 2023](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2023)\n - [— YEAR 2022](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2022)\n - [— YEAR 2021](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2021)\n - [— YEAR 2020](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2020)\n - [— YEAR 2019](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2019)\n - [— YEAR 2018](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2018)\n - [— YEAR 2017](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2017)\n - [— YEAR 2016](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2016)\n - [— YEAR 2015](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2015)\n - [— YEAR 2014](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2014)\n - [— YEAR 2013](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2013)\n - [— YEAR 2012](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2012)\n - [— YEAR 2011](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2011)\n - [— YEAR 2010](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2010)\n - [— YEAR 2009](https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings\/SEC%20Filings_2009)\n- [Careers](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:;)\n - [Our Talent](https:\/\/www.sinovac.com\/en-us\/careers\/talents)\n- [Contact Us](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/contact)\n\n- [联系我们](https:\/\/www.sinovac.com\/zh-cn\/contact)\n\n当前地点：\n\n[![](https:\/\/www.sinovac.com\/public\/images\/flag\/Global.gif) EN](https:\/\/www.sinovac.com\/en-us \"EN\")\n\n选择地点：\n\n- [![](https:\/\/www.sinovac.com\/public\/images\/flag\/cn.gif) 中文](\"中文\")\n- [![](https:\/\/www.sinovac.com\/public\/images\/flag\/Global.gif) EN](\"EN\")\n\n[![Logo Keywords](https:\/\/www.sinovac.com\/upload\/202212\/1672113932.svg)](https:\/\/www.sinovac.com\/en-us \"SINOVAC: Supply Vaccines to Eliminate Human Diseases\")\n\n- [Home](https:\/\/www.sinovac.com\/en-us)\n- [Company](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Company\")\n - [SINOVAC at Glance](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/about#met_148 \"SINOVAC at Glance\")\n - [Our History](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/about#met_438 \"Our History\")\n - [Social Responsibilities](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/about#met_433 \"Social Responsibilities\")\n- [News](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"News\")\n - [Press Releases](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/news#met_154 \"Press Releases\")\n - [Updates and Statements](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/news#met_155 \"Updates and Statements\")\n - [Media Asset Library](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/news#met_434 \"Media Asset Library\")\n- [Innovation](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Innovation\")\n - [Platform](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_167 \"Platform\")\n - [Pipeline](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_168 \"Pipeline\")\n - [Scientific Achievements](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_169 \"Scientific Achievements\")\n - [Partners](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/research#met_170 \"Partners\")\n- [Products](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Products\")\n - [Vaccines](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products#met_440 \"Vaccines\")\n - [International Business](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products#met_165 \"International Business\")\n - [Quality Management System](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products#met_173 \"Quality Management System\")\n - [Product Consultation](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/products\/consultation \"Product Consultation\")\n - [Adverse Event Report](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/aefi \"Adverse Event Report\")\n- [Investors](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Investors\")\n - [Corporate Governance](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/Investors\/corporate_governance\/Board_of_Directors \"Corporate Governance\")\n - [Financial Reports](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/Investors\/financial_reports \"Financial Reports\")\n - [SEC Filings](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/Investors\/sec_filings \"SEC Filings\")\n- [Careers](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20javascript:; \"Careers\")\n - [Our Talent](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.sinovac.com\/en-us\/careers\/talents \"Our Talent\")\n- [Contact Us](https:\/\/www.sinovac.com\/en-us\/contact)\n\n- [中文](\"中文\")\n- [EN](\"EN\")\n\n### Press Releases\nALL YEAR\n\n- [All](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIifQ%3D%3D \"All\")\n- [YEAR 2026](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTYifQ%3D%3D \"YEAR 2026\")\n- [YEAR 2025](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTMifQ%3D%3D \"YEAR 2025\")\n- [YEAR 2024](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTEifQ%3D%3D \"YEAR 2024\")\n- [YEAR 2023](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTIifQ%3D%3D \"YEAR 2023\")\n- [YEAR 2022](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTMifQ%3D%3D \"YEAR 2022\")\n- [YEAR 2021](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTQifQ%3D%3D \"YEAR 2021\")\n- [YEAR 2020](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTUifQ%3D%3D \"YEAR 2020\")\n- [YEAR 2019](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTYifQ%3D%3D \"YEAR 2019\")\n- [YEAR 2018](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTcifQ%3D%3D \"YEAR 2018\")\n- [YEAR 2017](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTgifQ%3D%3D \"YEAR 2017\")\n- [YEAR 2016](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTkifQ%3D%3D \"YEAR 2016\")\n- [YEAR 2015](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDAifQ%3D%3D \"YEAR 2015\")\n- [YEAR 2014](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDEifQ%3D%3D \"YEAR 2014\")\n- [YEAR 2013](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDIifQ%3D%3D \"YEAR 2013\")\n- [YEAR 2012](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDMifQ%3D%3D \"YEAR 2012\")\n- [YEAR 2011](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDQifQ%3D%3D \"YEAR 2011\")\n- [YEAR 2010](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDUifQ%3D%3D \"YEAR 2010\")\n- [YEAR 2009](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDYifQ%3D%3D \"YEAR 2009\")\n- [YEAR 2008](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDcifQ%3D%3D \"YEAR 2008\")\n- [YEAR 2007](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDgifQ%3D%3D \"YEAR 2007\")\n- [YEAR 2006](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDkifQ%3D%3D \"YEAR 2006\")\n- [YEAR 2005](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTAifQ%3D%3D \"YEAR 2005\")\n\n- 2022\/08\/20\n \n #### [Sinovac Beijing's QC Laboratory Accredited By CNAS](https:\/\/www.sinovac.com\/en-us\/news\/id-3162 \"Sinovac Beijing's QC Laboratory Accredited By CNAS\")\n [![Sinovac Beijing's QC Laboratory Accredited By CNAS]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3162 \"Sinovac Beijing's QC Laboratory Accredited By CNAS\")\n \n August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that the Qual\n- 2022\/08\/15\n \n #### [SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong](https:\/\/www.sinovac.com\/en-us\/news\/id-3156 \"SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong\")\n [![SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3156 \"SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong\")\n \n August 3, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat\n- 2022\/07\/19\n \n #### [SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile](https:\/\/www.sinovac.com\/en-us\/news\/id-3155 \"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile\")\n July 19, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli\n- 2022\/07\/14\n \n #### [SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil](https:\/\/www.sinovac.com\/en-us\/news\/id-3154 \"SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil\")\n July 14, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va\n- 2022\/07\/04\n \n #### [SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China](https:\/\/www.sinovac.com\/en-us\/news\/id-3153 \"SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China\")\n [![SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3153 \"SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China\")\n \n HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C\n- 2022\/06\/25\n \n #### [SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa](https:\/\/www.sinovac.com\/en-us\/news\/id-3142 \"SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa\")\n [![SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3142 \"SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa\")\n \n Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R\n- 2022\/06\/02\n \n #### [SINOVAC Polio Vaccine Prequalified by WHO](https:\/\/www.sinovac.com\/en-us\/news\/id-3131 \"SINOVAC Polio Vaccine Prequalified by WHO\")\n [![SINOVAC Polio Vaccine Prequalified by WHO]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3131 \"SINOVAC Polio Vaccine Prequalified by WHO\")\n \n BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal\n- 2022\/05\/26\n \n #### [Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population](https:\/\/www.sinovac.com\/en-us\/news\/id-3125 \"Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population\")\n On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report \"AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent\n- 2022\/05\/11\n \n #### [SINOVAC Honored \"MITRA BUMN GLOBAL CHAMPION 2022\" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine](https:\/\/www.sinovac.com\/en-us\/news\/id-3118 \"SINOVAC Honored \")\n [![SINOVAC Honored ]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3118 \"SINOVAC Honored \")\n \n May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the \"MITRA BUMN GLOBAL CHAMPION 2022\" awa\n- 2022\/04\/30\n \n #### [SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F](https:\/\/www.sinovac.com\/en-us\/news\/id-3111 \"SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F\")\n [![SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3111 \"SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F\")\n \n BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S.\n- 2022\/04\/26\n \n #### [China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](https:\/\/www.sinovac.com\/en-us\/news\/id-3109 \"China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial\")\n [![China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3109 \"China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial\")\n \n April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de\n- 2022\/04\/17\n \n #### [SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong](https:\/\/www.sinovac.com\/en-us\/news\/id-3105 \"SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong\")\n [![SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3105 \"SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong\")\n \n April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie\n- 2022\/03\/23\n \n #### [Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave](https:\/\/www.sinovac.com\/en-us\/news\/id-3089 \"Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave\")\n [![Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3089 \"Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave\")\n \n A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of\n- 2022\/03\/16\n \n #### [Chile Research: CoronaVac® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old](https:\/\/www.sinovac.com\/en-us\/news\/id-3012 \"Chile Research: CoronaVac®<\/sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old\")\n [![Chile Research: CoronaVac\\<sup\\>®\\<\/sup\\> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3012 \"Chile Research: CoronaVac®<\/sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old\")\n \n The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and\n- 2022\/03\/16\n \n #### [Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak](https:\/\/www.sinovac.com\/en-us\/news\/id-3086 \"Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak\")\n [![Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3086 \"Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak\")\n \n On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen\n- 2022\/03\/16\n \n #### [Latest Real-World Data Show Two-shots of CoronaVac® Provides 74.5% Protection Against COVID-19 For Children and Adolescents](https:\/\/www.sinovac.com\/en-us\/news\/id-3083 \"Latest Real-World Data Show Two-shots of CoronaVac®<\/sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents\")\n [![Latest Real-World Data Show Two-shots of CoronaVac\\<sup\\>®\\<\/sup\\> Provides 74.5% Protection Against COVID-19 For Children and Adolescents]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3083 \"Latest Real-World Data Show Two-shots of CoronaVac®<\/sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents\")\n \n Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi\n- 2022\/03\/04\n \n #### [Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided](https:\/\/www.sinovac.com\/en-us\/news\/id-3082 \"Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided\")\n [![Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3082 \"Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided\")\n \n During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p\n- 2022\/02\/25\n \n #### [CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony](https:\/\/www.sinovac.com\/en-us\/news\/id-3063 \"CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony\")\n [![CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3063 \"CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony\")\n \n Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C\n- 2022\/02\/18\n \n #### [CUHK and SINOVAC join in hands in building P3 laboratory](https:\/\/www.sinovac.com\/en-us\/news\/id-3065 \"CUHK and SINOVAC join in hands in building P3 laboratory\")\n [![CUHK and SINOVAC join in hands in building P3 laboratory]()](https:\/\/www.sinovac.com\/en-us\/news\/id-3065 \"CUHK and SINOVAC join in hands in building P3 laboratory\")\n \n Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework\n- 2021\/12\/31\n \n #### [SINOVAC Reports Unaudited First Half of 2021 Financial Results](https:\/\/www.sinovac.com\/en-us\/news\/id-3038 \"SINOVAC Reports Unaudited First Half of 2021 Financial Results\")\n BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results\n\n[Previous page](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/4)[1\\...](https:\/\/www.sinovac.com\/en-us\/news\/release)[2](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/2)[3](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/3)[4](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/4)[5](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/5)[6](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/6)[7](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/7)[8](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/8)[...26](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/26)[Next page](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/6) Go to No.\n\n![Logo Keywords](https:\/\/www.sinovac.com\/upload\/202212\/1672113442.svg)\n\n- Follow Us\n- [![ins](https:\/\/www.sinovac.com\/upload\/202301\/1673426012.svg)](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.instagram.com\/sinovacbiotech\/)\n- [![twitter-en](https:\/\/www.sinovac.com\/upload\/202309\/1695798095.svg)](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/twitter.com\/Sinovac)\n- [![twitter-esp](https:\/\/www.sinovac.com\/upload\/202309\/1695797364.svg)](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/twitter.com\/Sinovac)\n- [![facebook](https:\/\/www.sinovac.com\/upload\/202305\/1685341865.png)](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.facebook.com\/SinovacBiotechSVA)\n- [![youtube](https:\/\/www.sinovac.com\/upload\/202301\/1673425800.svg)](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.youtube.com\/@SinovacBiotech)\n- [![LinkedIn](https:\/\/www.sinovac.com\/upload\/202305\/1685082845.png)](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/%20%20%20%20https:\/\/www.linkedin.com\/company\/sinovac-biotech-ltd.\/)\n\n![]()\n\n© SINOVAC All rights reserved","attrs_readable_markdown":"### Press Releases\nALL YEAR\n\n- [All](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIifQ%3D%3D \"All\")\n- [YEAR 2026](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTYifQ%3D%3D \"YEAR 2026\")\n- [YEAR 2025](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTMifQ%3D%3D \"YEAR 2025\")\n- [YEAR 2024](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTEifQ%3D%3D \"YEAR 2024\")\n- [YEAR 2023](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTIifQ%3D%3D \"YEAR 2023\")\n- [YEAR 2022](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTMifQ%3D%3D \"YEAR 2022\")\n- [YEAR 2021](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTQifQ%3D%3D \"YEAR 2021\")\n- [YEAR 2020](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTUifQ%3D%3D \"YEAR 2020\")\n- [YEAR 2019](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTYifQ%3D%3D \"YEAR 2019\")\n- [YEAR 2018](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTcifQ%3D%3D \"YEAR 2018\")\n- [YEAR 2017](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTgifQ%3D%3D \"YEAR 2017\")\n- [YEAR 2016](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiIzOTkifQ%3D%3D \"YEAR 2016\")\n- [YEAR 2015](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDAifQ%3D%3D \"YEAR 2015\")\n- [YEAR 2014](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDEifQ%3D%3D \"YEAR 2014\")\n- [YEAR 2013](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDIifQ%3D%3D \"YEAR 2013\")\n- [YEAR 2012](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDMifQ%3D%3D \"YEAR 2012\")\n- [YEAR 2011](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDQifQ%3D%3D \"YEAR 2011\")\n- [YEAR 2010](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDUifQ%3D%3D \"YEAR 2010\")\n- [YEAR 2009](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDYifQ%3D%3D \"YEAR 2009\")\n- [YEAR 2008](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDcifQ%3D%3D \"YEAR 2008\")\n- [YEAR 2007](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDgifQ%3D%3D \"YEAR 2007\")\n- [YEAR 2006](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MDkifQ%3D%3D \"YEAR 2006\")\n- [YEAR 2005](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/1&search=search&para=eyI0NzYiOiI0MTAifQ%3D%3D \"YEAR 2005\")\n\n- 2022\/08\/20\n \n #### [Sinovac Beijing's QC Laboratory Accredited By CNAS](https:\/\/www.sinovac.com\/en-us\/news\/id-3162 \"Sinovac Beijing's QC Laboratory Accredited By CNAS\")\n [![Sinovac Beijing's QC Laboratory Accredited By CNAS](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1660966739.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3162 \"Sinovac Beijing's QC Laboratory Accredited By CNAS\")\n \n August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that the Qual\n- 2022\/08\/15\n \n #### [SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong](https:\/\/www.sinovac.com\/en-us\/news\/id-3156 \"SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong\")\n August 3, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat\n- 2022\/07\/19\n \n #### [SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile](https:\/\/www.sinovac.com\/en-us\/news\/id-3155 \"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile\")\n July 19, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli\n- 2022\/07\/14\n \n #### [SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil](https:\/\/www.sinovac.com\/en-us\/news\/id-3154 \"SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil\")\n July 14, 2022, Beijing -- Sinovac Biotech Ltd. (\"SINOVAC\" or the \"Company\") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va\n- 2022\/07\/04\n \n #### [SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China](https:\/\/www.sinovac.com\/en-us\/news\/id-3153 \"SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China\")\n HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C\n- 2022\/06\/25\n \n #### [SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa](https:\/\/www.sinovac.com\/en-us\/news\/id-3142 \"SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa\")\n [![SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1656136764736555.jpg)](https:\/\/www.sinovac.com\/en-us\/news\/id-3142 \"SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa\")\n \n Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R\n- 2022\/06\/02\n \n #### [SINOVAC Polio Vaccine Prequalified by WHO](https:\/\/www.sinovac.com\/en-us\/news\/id-3131 \"SINOVAC Polio Vaccine Prequalified by WHO\")\n [![SINOVAC Polio Vaccine Prequalified by WHO](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1654746510276884.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3131 \"SINOVAC Polio Vaccine Prequalified by WHO\")\n \n BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal\n- 2022\/05\/26\n \n #### [Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population](https:\/\/www.sinovac.com\/en-us\/news\/id-3125 \"Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population\")\n On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report \"AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent\n- 2022\/05\/11\n \n #### [SINOVAC Honored \"MITRA BUMN GLOBAL CHAMPION 2022\" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine](https:\/\/www.sinovac.com\/en-us\/news\/id-3118 \"SINOVAC Honored \")\n [![SINOVAC Honored ](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1652263684869344.jpg)](https:\/\/www.sinovac.com\/en-us\/news\/id-3118 \"SINOVAC Honored \")\n \n May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the \"MITRA BUMN GLOBAL CHAMPION 2022\" awa\n- 2022\/04\/30\n \n #### [SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F](https:\/\/www.sinovac.com\/en-us\/news\/id-3111 \"SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F\")\n [![SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1651281223.jpg)](https:\/\/www.sinovac.com\/en-us\/news\/id-3111 \"SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F\")\n \n BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S.\n- 2022\/04\/26\n \n #### [China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](https:\/\/www.sinovac.com\/en-us\/news\/id-3109 \"China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial\")\n [![China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1650965129.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3109 \"China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial\")\n \n April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de\n- 2022\/04\/17\n \n #### [SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong](https:\/\/www.sinovac.com\/en-us\/news\/id-3105 \"SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong\")\n [![SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1650164752.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3105 \"SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong\")\n \n April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie\n- 2022\/03\/23\n \n #### [Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave](https:\/\/www.sinovac.com\/en-us\/news\/id-3089 \"Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave\")\n [![Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1648008373.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3089 \"Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave\")\n \n A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of\n- 2022\/03\/16\n \n #### [Chile Research: CoronaVac® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old](https:\/\/www.sinovac.com\/en-us\/news\/id-3012 \"Chile Research: CoronaVac®<\/sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old\")\n [![Chile Research: CoronaVac\\<sup\\>®\\<\/sup\\> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1647403470.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3012 \"Chile Research: CoronaVac®<\/sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old\")\n \n The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and\n- 2022\/03\/16\n \n #### [Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak](https:\/\/www.sinovac.com\/en-us\/news\/id-3086 \"Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak\")\n [![Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1647483491.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3086 \"Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak\")\n \n On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen\n- 2022\/03\/16\n \n #### [Latest Real-World Data Show Two-shots of CoronaVac® Provides 74.5% Protection Against COVID-19 For Children and Adolescents](https:\/\/www.sinovac.com\/en-us\/news\/id-3083 \"Latest Real-World Data Show Two-shots of CoronaVac®<\/sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents\")\n [![Latest Real-World Data Show Two-shots of CoronaVac\\<sup\\>®\\<\/sup\\> Provides 74.5% Protection Against COVID-19 For Children and Adolescents](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1647422686.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3083 \"Latest Real-World Data Show Two-shots of CoronaVac®<\/sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents\")\n \n Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi\n- 2022\/03\/04\n \n #### [Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided](https:\/\/www.sinovac.com\/en-us\/news\/id-3082 \"Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided\")\n [![Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1646402303601397.jpg)](https:\/\/www.sinovac.com\/en-us\/news\/id-3082 \"Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided\")\n \n During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p\n- 2022\/02\/25\n \n #### [CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony](https:\/\/www.sinovac.com\/en-us\/news\/id-3063 \"CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony\")\n [![CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1647342724.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3063 \"CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony\")\n \n Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C\n- 2022\/02\/18\n \n #### [CUHK and SINOVAC join in hands in building P3 laboratory](https:\/\/www.sinovac.com\/en-us\/news\/id-3065 \"CUHK and SINOVAC join in hands in building P3 laboratory\")\n [![CUHK and SINOVAC join in hands in building P3 laboratory](https:\/\/www.sinovac.com\/upload\/thumb_src\/800_500\/1647334058.png)](https:\/\/www.sinovac.com\/en-us\/news\/id-3065 \"CUHK and SINOVAC join in hands in building P3 laboratory\")\n \n Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework\n- 2021\/12\/31\n \n #### [SINOVAC Reports Unaudited First Half of 2021 Financial Results](https:\/\/www.sinovac.com\/en-us\/news\/id-3038 \"SINOVAC Reports Unaudited First Half of 2021 Financial Results\")\n BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (\"SINOVAC\" or the \"Company\"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results\n\n[Previous page](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/4)[1\\...](https:\/\/www.sinovac.com\/en-us\/news\/release)[2](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/2)[3](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/3)[4](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/4)[5](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/5)[6](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/6)[7](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/7)[8](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/8)[...26](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/26)[Next page](https:\/\/www.sinovac.com\/en-us\/news\/release\/page\/6) Go to No.","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

2 days ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.1 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://www.sinovac.com/en-us/news/release/page/5
Last Crawled	2026-04-14 12:44:52 (2 days ago)
First Indexed	2025-02-25 20:41:40 (1 year ago)
HTTP Status Code	200
Meta Title	Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases-page5
Meta Description	SINOVAC: Supply Vaccines to Eliminate Human Diseases
Meta Canonical	null
Boilerpipe Text	Press Releases ALL YEAR All YEAR 2026 YEAR 2025 YEAR 2024 YEAR 2023 YEAR 2022 YEAR 2021 YEAR 2020 YEAR 2019 YEAR 2018 YEAR 2017 YEAR 2016 YEAR 2015 YEAR 2014 YEAR 2013 YEAR 2012 YEAR 2011 YEAR 2010 YEAR 2009 YEAR 2008 YEAR 2007 YEAR 2006 YEAR 2005 2022/08/20 Sinovac Beijing's QC Laboratory Accredited By CNAS August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Qual 2022/08/15 SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong August 3, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat 2022/07/19 SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile July 19, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli 2022/07/14 SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil July 14, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va 2022/07/04 SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C 2022/06/25 SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R 2022/06/02 SINOVAC Polio Vaccine Prequalified by WHO BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal 2022/05/26 Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report "AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent 2022/05/11 SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" awa 2022/04/30 SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. 2022/04/26 China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de 2022/04/17 SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie 2022/03/23 Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of 2022/03/16 Chile Research: CoronaVac ® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and 2022/03/16 Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen 2022/03/16 Latest Real-World Data Show Two-shots of CoronaVac ® Provides 74.5% Protection Against COVID-19 For Children and Adolescents Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi 2022/03/04 Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p 2022/02/25 CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C 2022/02/18 CUHK and SINOVAC join in hands in building P3 laboratory Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework 2021/12/31 SINOVAC Reports Unaudited First Half of 2021 Financial Results BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results Previous page 1... 2 3 4 5 6 7 8 ...26 Next page Go to No.
Markdown	[![Logo Keywords](https://www.sinovac.com/upload/202212/1672113330.svg)](https://www.sinovac.com/en-us "SINOVAC: Supply Vaccines to Eliminate Human Diseases") - [Company](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Company") - [SINOVAC at Glance](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/about#met_148) - [Our History](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/about#met_438) - [Social Responsibilities](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/about#met_433) - [Innovation](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Innovation") - [Platform](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_167) - [Pipeline](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_168) - [Scientific Achievements](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_169) - [Partners](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_170) - [— Research Institute](https://www.sinovac.com/en-us/research/partners/Research_Institute) - [— Universities](https://www.sinovac.com/en-us/research/partners/Universities) - [— Medical Institutions](https://www.sinovac.com/en-us/research/partners/Medical_institutions) - [— Companies](https://www.sinovac.com/en-us/research/partners/companies) - [Products](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Products") - [Vaccines](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products#met_440) - [International Business](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products#met_165) - [Quality Management System](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products#met_173) - [Product Consultation](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products/consultation) - [Adverse Event Report](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/aefi) - [News](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "News") - [Press Releases](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/news#met_154) - [Updates and Statements](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/news#met_155) - [Media Asset Library](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/news#met_434) - [Investors](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Investors") - [Corporate Governance](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/Investors/corporate_governance/Board_of_Directors) - [Financial Reports](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/Investors/financial_reports) - [SEC Filings](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/Investors/sec_filings) - [Careers](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Careers") - [Our Talent](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/careers/talents) - [中文]("链接关键词") [EN]("链接关键词") - [Contact Us](https://www.sinovac.com/en-us/contact) - [Company](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:;) - [SINOVAC at Glance](https://www.sinovac.com/en-us/about/at_glance_cn) - [Our History](https://www.sinovac.com/en-us/about/Our_History) - [Social Responsibilities](https://www.sinovac.com/en-us/about/Responsibilities) - [News](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:;) - [Press Releases](https://www.sinovac.com/en-us/news/release) - [Updates and Statements](https://www.sinovac.com/en-us/news/coverage) - [Media Asset Library](https://www.sinovac.com/en-us/news/Media) - [— Logo](https://www.sinovac.com/en-us/download2/class-435) - [— Vaccines](https://www.sinovac.com/en-us/download2/class-436) - [Innovation](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:;) - [Platform](https://www.sinovac.com/en-us/research/platform) - [Pipeline](https://www.sinovac.com/en-us/research/pipeline) - [Scientific Achievements](https://www.sinovac.com/en-us/research/achievements) - [Partners](https://www.sinovac.com/en-us/research/partners) - [— Research Institute](https://www.sinovac.com/en-us/research/partners/Research_Institute) - [— Universities](https://www.sinovac.com/en-us/research/partners/Universities) - [— Medical Institutions](https://www.sinovac.com/en-us/research/partners/Medical_institutions) - [— Companies](https://www.sinovac.com/en-us/research/partners/companies) - [Products](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:;) - [Vaccines](https://www.sinovac.com/en-us/products/portfolio) - [International Business](https://www.sinovac.com/en-us/products/international-business) - [Quality Management System](https://www.sinovac.com/en-us/products/publicity) - [Product Consultation](https://www.sinovac.com/en-us/products/consultation) - [Adverse Event Report](https://www.sinovac.com/en-us/aefi) - [Investors](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:;) - [Corporate Governance](https://www.sinovac.com/en-us/Investors/corporate_governance/Board_of_Directors) - [— Board of Directors](https://www.sinovac.com/en-us/Investors/corporate_governance/Board_of_Directors) - [— Board Committees & Charters](https://www.sinovac.com/en-us/Investors/corporate_governance/Board_Committees_and_Charters) - [Financial Reports](https://www.sinovac.com/en-us/Investors/financial_reports) - [— YEAR 2024](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2023) - [— YEAR 2023](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2024) - [— YEAR 2021](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2021) - [— YEAR 2022](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2022) - [— YEAR 2020](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2020) - [— YEAR 2019](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2019) - [— YEAR 2018](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2018) - [— YEAR 2017](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2017) - [— YEAR 2016](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2016) - [— YEAR 2015](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2015) - [— YEAR 2014](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2014) - [— YEAR 2013](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2013) - [— YEAR 2012](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2012) - [— YEAR 2011](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2011) - [— YEAR 2010](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2010) - [— YEAR 2009](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2009) - [— YEAR 2008](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2008) - [— YEAR 2007](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2007) - [— YEAR 2006](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2006) - [— YEAR 2005](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2005) - [— YEAR 2004](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2004) - [— YEAR 2003](https://www.sinovac.com/en-us/Investors/financial_reports/financial_reports_2003) - [SEC Filings](https://www.sinovac.com/en-us/Investors/sec_filings) - [— YEAR 2025](https://www.sinovac.com/en-us/Investors/sec_filings/sec_filings2025) - [— YEAR 2024](https://www.sinovac.com/en-us/Investors/sec_filings/SEC) - [— YEAR 2023](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2023) - [— YEAR 2022](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2022) - [— YEAR 2021](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2021) - [— YEAR 2020](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2020) - [— YEAR 2019](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2019) - [— YEAR 2018](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2018) - [— YEAR 2017](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2017) - [— YEAR 2016](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2016) - [— YEAR 2015](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2015) - [— YEAR 2014](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2014) - [— YEAR 2013](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2013) - [— YEAR 2012](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2012) - [— YEAR 2011](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2011) - [— YEAR 2010](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2010) - [— YEAR 2009](https://www.sinovac.com/en-us/Investors/sec_filings/SEC%20Filings_2009) - [Careers](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:;) - [Our Talent](https://www.sinovac.com/en-us/careers/talents) - [Contact Us](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/contact) - [联系我们](https://www.sinovac.com/zh-cn/contact) 当前地点： [![](https://www.sinovac.com/public/images/flag/Global.gif) EN](https://www.sinovac.com/en-us "EN") 选择地点： - [![](https://www.sinovac.com/public/images/flag/cn.gif) 中文]("中文") - [![](https://www.sinovac.com/public/images/flag/Global.gif) EN]("EN") [![Logo Keywords](https://www.sinovac.com/upload/202212/1672113932.svg)](https://www.sinovac.com/en-us "SINOVAC: Supply Vaccines to Eliminate Human Diseases") - [Home](https://www.sinovac.com/en-us) - [Company](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Company") - [SINOVAC at Glance](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/about#met_148 "SINOVAC at Glance") - [Our History](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/about#met_438 "Our History") - [Social Responsibilities](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/about#met_433 "Social Responsibilities") - [News](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "News") - [Press Releases](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/news#met_154 "Press Releases") - [Updates and Statements](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/news#met_155 "Updates and Statements") - [Media Asset Library](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/news#met_434 "Media Asset Library") - [Innovation](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Innovation") - [Platform](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_167 "Platform") - [Pipeline](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_168 "Pipeline") - [Scientific Achievements](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_169 "Scientific Achievements") - [Partners](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/research#met_170 "Partners") - [Products](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Products") - [Vaccines](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products#met_440 "Vaccines") - [International Business](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products#met_165 "International Business") - [Quality Management System](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products#met_173 "Quality Management System") - [Product Consultation](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/products/consultation "Product Consultation") - [Adverse Event Report](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/aefi "Adverse Event Report") - [Investors](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Investors") - [Corporate Governance](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/Investors/corporate_governance/Board_of_Directors "Corporate Governance") - [Financial Reports](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/Investors/financial_reports "Financial Reports") - [SEC Filings](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/Investors/sec_filings "SEC Filings") - [Careers](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20javascript:; "Careers") - [Our Talent](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.sinovac.com/en-us/careers/talents "Our Talent") - [Contact Us](https://www.sinovac.com/en-us/contact) - [中文]("中文") - [EN]("EN") ### Press Releases ALL YEAR - [All](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIifQ%3D%3D "All") - [YEAR 2026](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTYifQ%3D%3D "YEAR 2026") - [YEAR 2025](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTMifQ%3D%3D "YEAR 2025") - [YEAR 2024](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTEifQ%3D%3D "YEAR 2024") - [YEAR 2023](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTIifQ%3D%3D "YEAR 2023") - [YEAR 2022](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTMifQ%3D%3D "YEAR 2022") - [YEAR 2021](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTQifQ%3D%3D "YEAR 2021") - [YEAR 2020](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTUifQ%3D%3D "YEAR 2020") - [YEAR 2019](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTYifQ%3D%3D "YEAR 2019") - [YEAR 2018](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTcifQ%3D%3D "YEAR 2018") - [YEAR 2017](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTgifQ%3D%3D "YEAR 2017") - [YEAR 2016](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTkifQ%3D%3D "YEAR 2016") - [YEAR 2015](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDAifQ%3D%3D "YEAR 2015") - [YEAR 2014](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDEifQ%3D%3D "YEAR 2014") - [YEAR 2013](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDIifQ%3D%3D "YEAR 2013") - [YEAR 2012](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDMifQ%3D%3D "YEAR 2012") - [YEAR 2011](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDQifQ%3D%3D "YEAR 2011") - [YEAR 2010](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDUifQ%3D%3D "YEAR 2010") - [YEAR 2009](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDYifQ%3D%3D "YEAR 2009") - [YEAR 2008](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDcifQ%3D%3D "YEAR 2008") - [YEAR 2007](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDgifQ%3D%3D "YEAR 2007") - [YEAR 2006](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDkifQ%3D%3D "YEAR 2006") - [YEAR 2005](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTAifQ%3D%3D "YEAR 2005") - 2022/08/20 #### [Sinovac Beijing's QC Laboratory Accredited By CNAS](https://www.sinovac.com/en-us/news/id-3162 "Sinovac Beijing's QC Laboratory Accredited By CNAS") [![Sinovac Beijing's QC Laboratory Accredited By CNAS]()](https://www.sinovac.com/en-us/news/id-3162 "Sinovac Beijing's QC Laboratory Accredited By CNAS") August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Qual - 2022/08/15 #### [SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong](https://www.sinovac.com/en-us/news/id-3156 "SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong") [![SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong]()](https://www.sinovac.com/en-us/news/id-3156 "SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong") August 3, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat - 2022/07/19 #### [SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile](https://www.sinovac.com/en-us/news/id-3155 "SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile") July 19, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli - 2022/07/14 #### [SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil](https://www.sinovac.com/en-us/news/id-3154 "SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil") July 14, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va - 2022/07/04 #### [SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China](https://www.sinovac.com/en-us/news/id-3153 "SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China") [![SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China]()](https://www.sinovac.com/en-us/news/id-3153 "SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China") HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C - 2022/06/25 #### [SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa](https://www.sinovac.com/en-us/news/id-3142 "SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa") [![SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa]()](https://www.sinovac.com/en-us/news/id-3142 "SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa") Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R - 2022/06/02 #### [SINOVAC Polio Vaccine Prequalified by WHO](https://www.sinovac.com/en-us/news/id-3131 "SINOVAC Polio Vaccine Prequalified by WHO") [![SINOVAC Polio Vaccine Prequalified by WHO]()](https://www.sinovac.com/en-us/news/id-3131 "SINOVAC Polio Vaccine Prequalified by WHO") BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal - 2022/05/26 #### [Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population](https://www.sinovac.com/en-us/news/id-3125 "Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population") On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report "AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent - 2022/05/11 #### [SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine](https://www.sinovac.com/en-us/news/id-3118 "SINOVAC Honored ") [![SINOVAC Honored ]()](https://www.sinovac.com/en-us/news/id-3118 "SINOVAC Honored ") May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" awa - 2022/04/30 #### [SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F](https://www.sinovac.com/en-us/news/id-3111 "SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F") [![SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F]()](https://www.sinovac.com/en-us/news/id-3111 "SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F") BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. - 2022/04/26 #### [China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](https://www.sinovac.com/en-us/news/id-3109 "China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial") [![China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial]()](https://www.sinovac.com/en-us/news/id-3109 "China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial") April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de - 2022/04/17 #### [SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong](https://www.sinovac.com/en-us/news/id-3105 "SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong") [![SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong]()](https://www.sinovac.com/en-us/news/id-3105 "SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong") April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie - 2022/03/23 #### [Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave](https://www.sinovac.com/en-us/news/id-3089 "Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave") [![Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave]()](https://www.sinovac.com/en-us/news/id-3089 "Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave") A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of - 2022/03/16 #### [Chile Research: CoronaVac® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old](https://www.sinovac.com/en-us/news/id-3012 "Chile Research: CoronaVac<sup>®</sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old") [![Chile Research: CoronaVac\<sup\>®\</sup\> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old]()](https://www.sinovac.com/en-us/news/id-3012 "Chile Research: CoronaVac<sup>®</sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old") The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and - 2022/03/16 #### [Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak](https://www.sinovac.com/en-us/news/id-3086 "Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak") [![Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak]()](https://www.sinovac.com/en-us/news/id-3086 "Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak") On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen - 2022/03/16 #### [Latest Real-World Data Show Two-shots of CoronaVac® Provides 74.5% Protection Against COVID-19 For Children and Adolescents](https://www.sinovac.com/en-us/news/id-3083 "Latest Real-World Data Show Two-shots of CoronaVac<sup>®</sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents") [![Latest Real-World Data Show Two-shots of CoronaVac\<sup\>®\</sup\> Provides 74.5% Protection Against COVID-19 For Children and Adolescents]()](https://www.sinovac.com/en-us/news/id-3083 "Latest Real-World Data Show Two-shots of CoronaVac<sup>®</sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents") Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi - 2022/03/04 #### [Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided](https://www.sinovac.com/en-us/news/id-3082 "Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided") [![Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided]()](https://www.sinovac.com/en-us/news/id-3082 "Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided") During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p - 2022/02/25 #### [CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony](https://www.sinovac.com/en-us/news/id-3063 "CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony") [![CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony]()](https://www.sinovac.com/en-us/news/id-3063 "CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony") Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C - 2022/02/18 #### [CUHK and SINOVAC join in hands in building P3 laboratory](https://www.sinovac.com/en-us/news/id-3065 "CUHK and SINOVAC join in hands in building P3 laboratory") [![CUHK and SINOVAC join in hands in building P3 laboratory]()](https://www.sinovac.com/en-us/news/id-3065 "CUHK and SINOVAC join in hands in building P3 laboratory") Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework - 2021/12/31 #### [SINOVAC Reports Unaudited First Half of 2021 Financial Results](https://www.sinovac.com/en-us/news/id-3038 "SINOVAC Reports Unaudited First Half of 2021 Financial Results") BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results [Previous page](https://www.sinovac.com/en-us/news/release/page/4)[1\...](https://www.sinovac.com/en-us/news/release)[2](https://www.sinovac.com/en-us/news/release/page/2)[3](https://www.sinovac.com/en-us/news/release/page/3)[4](https://www.sinovac.com/en-us/news/release/page/4)[5](https://www.sinovac.com/en-us/news/release/page/5)[6](https://www.sinovac.com/en-us/news/release/page/6)[7](https://www.sinovac.com/en-us/news/release/page/7)[8](https://www.sinovac.com/en-us/news/release/page/8)[...26](https://www.sinovac.com/en-us/news/release/page/26)[Next page](https://www.sinovac.com/en-us/news/release/page/6) Go to No. ![Logo Keywords](https://www.sinovac.com/upload/202212/1672113442.svg) - Follow Us - [![ins](https://www.sinovac.com/upload/202301/1673426012.svg)](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.instagram.com/sinovacbiotech/) - [![twitter-en](https://www.sinovac.com/upload/202309/1695798095.svg)](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://twitter.com/Sinovac) - [![twitter-esp](https://www.sinovac.com/upload/202309/1695797364.svg)](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://twitter.com/Sinovac) - [![facebook](https://www.sinovac.com/upload/202305/1685341865.png)](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.facebook.com/SinovacBiotechSVA) - [![youtube](https://www.sinovac.com/upload/202301/1673425800.svg)](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.youtube.com/@SinovacBiotech) - [![LinkedIn](https://www.sinovac.com/upload/202305/1685082845.png)](https://www.sinovac.com/en-us/news/release/page/%20%20%20%20https://www.linkedin.com/company/sinovac-biotech-ltd./) ![]() © SINOVAC All rights reserved
Readable Markdown	### Press Releases ALL YEAR - [All](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIifQ%3D%3D "All") - [YEAR 2026](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTYifQ%3D%3D "YEAR 2026") - [YEAR 2025](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTMifQ%3D%3D "YEAR 2025") - [YEAR 2024](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTEifQ%3D%3D "YEAR 2024") - [YEAR 2023](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTIifQ%3D%3D "YEAR 2023") - [YEAR 2022](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTMifQ%3D%3D "YEAR 2022") - [YEAR 2021](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTQifQ%3D%3D "YEAR 2021") - [YEAR 2020](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTUifQ%3D%3D "YEAR 2020") - [YEAR 2019](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTYifQ%3D%3D "YEAR 2019") - [YEAR 2018](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTcifQ%3D%3D "YEAR 2018") - [YEAR 2017](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTgifQ%3D%3D "YEAR 2017") - [YEAR 2016](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiIzOTkifQ%3D%3D "YEAR 2016") - [YEAR 2015](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDAifQ%3D%3D "YEAR 2015") - [YEAR 2014](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDEifQ%3D%3D "YEAR 2014") - [YEAR 2013](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDIifQ%3D%3D "YEAR 2013") - [YEAR 2012](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDMifQ%3D%3D "YEAR 2012") - [YEAR 2011](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDQifQ%3D%3D "YEAR 2011") - [YEAR 2010](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDUifQ%3D%3D "YEAR 2010") - [YEAR 2009](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDYifQ%3D%3D "YEAR 2009") - [YEAR 2008](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDcifQ%3D%3D "YEAR 2008") - [YEAR 2007](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDgifQ%3D%3D "YEAR 2007") - [YEAR 2006](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MDkifQ%3D%3D "YEAR 2006") - [YEAR 2005](https://www.sinovac.com/en-us/news/release/page/1&search=search&para=eyI0NzYiOiI0MTAifQ%3D%3D "YEAR 2005") - 2022/08/20 #### [Sinovac Beijing's QC Laboratory Accredited By CNAS](https://www.sinovac.com/en-us/news/id-3162 "Sinovac Beijing's QC Laboratory Accredited By CNAS") [![Sinovac Beijing's QC Laboratory Accredited By CNAS](https://www.sinovac.com/upload/thumb_src/800_500/1660966739.png)](https://www.sinovac.com/en-us/news/id-3162 "Sinovac Beijing's QC Laboratory Accredited By CNAS") August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Qual - 2022/08/15 #### [SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong](https://www.sinovac.com/en-us/news/id-3156 "SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong") August 3, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat - 2022/07/19 #### [SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile](https://www.sinovac.com/en-us/news/id-3155 "SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile") July 19, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli - 2022/07/14 #### [SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil](https://www.sinovac.com/en-us/news/id-3154 "SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil") July 14, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va - 2022/07/04 #### [SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China](https://www.sinovac.com/en-us/news/id-3153 "SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China") HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C - 2022/06/25 #### [SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa](https://www.sinovac.com/en-us/news/id-3142 "SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa") [![SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa](https://www.sinovac.com/upload/thumb_src/800_500/1656136764736555.jpg)](https://www.sinovac.com/en-us/news/id-3142 "SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa") Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R - 2022/06/02 #### [SINOVAC Polio Vaccine Prequalified by WHO](https://www.sinovac.com/en-us/news/id-3131 "SINOVAC Polio Vaccine Prequalified by WHO") [![SINOVAC Polio Vaccine Prequalified by WHO](https://www.sinovac.com/upload/thumb_src/800_500/1654746510276884.png)](https://www.sinovac.com/en-us/news/id-3131 "SINOVAC Polio Vaccine Prequalified by WHO") BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal - 2022/05/26 #### [Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population](https://www.sinovac.com/en-us/news/id-3125 "Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population") On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report "AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent - 2022/05/11 #### [SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine](https://www.sinovac.com/en-us/news/id-3118 "SINOVAC Honored ") [![SINOVAC Honored ](https://www.sinovac.com/upload/thumb_src/800_500/1652263684869344.jpg)](https://www.sinovac.com/en-us/news/id-3118 "SINOVAC Honored ") May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" awa - 2022/04/30 #### [SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F](https://www.sinovac.com/en-us/news/id-3111 "SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F") [![SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F](https://www.sinovac.com/upload/thumb_src/800_500/1651281223.jpg)](https://www.sinovac.com/en-us/news/id-3111 "SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F") BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. - 2022/04/26 #### [China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](https://www.sinovac.com/en-us/news/id-3109 "China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial") [![China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](https://www.sinovac.com/upload/thumb_src/800_500/1650965129.png)](https://www.sinovac.com/en-us/news/id-3109 "China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial") April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de - 2022/04/17 #### [SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong](https://www.sinovac.com/en-us/news/id-3105 "SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong") [![SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong](https://www.sinovac.com/upload/thumb_src/800_500/1650164752.png)](https://www.sinovac.com/en-us/news/id-3105 "SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong") April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie - 2022/03/23 #### [Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave](https://www.sinovac.com/en-us/news/id-3089 "Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave") [![Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave](https://www.sinovac.com/upload/thumb_src/800_500/1648008373.png)](https://www.sinovac.com/en-us/news/id-3089 "Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave") A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of - 2022/03/16 #### [Chile Research: CoronaVac® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old](https://www.sinovac.com/en-us/news/id-3012 "Chile Research: CoronaVac<sup>®</sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old") [![Chile Research: CoronaVac\<sup\>®\</sup\> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old](https://www.sinovac.com/upload/thumb_src/800_500/1647403470.png)](https://www.sinovac.com/en-us/news/id-3012 "Chile Research: CoronaVac<sup>®</sup> is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old") The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and - 2022/03/16 #### [Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak](https://www.sinovac.com/en-us/news/id-3086 "Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak") [![Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak](https://www.sinovac.com/upload/thumb_src/800_500/1647483491.png)](https://www.sinovac.com/en-us/news/id-3086 "Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak") On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen - 2022/03/16 #### [Latest Real-World Data Show Two-shots of CoronaVac® Provides 74.5% Protection Against COVID-19 For Children and Adolescents](https://www.sinovac.com/en-us/news/id-3083 "Latest Real-World Data Show Two-shots of CoronaVac<sup>®</sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents") [![Latest Real-World Data Show Two-shots of CoronaVac\<sup\>®\</sup\> Provides 74.5% Protection Against COVID-19 For Children and Adolescents](https://www.sinovac.com/upload/thumb_src/800_500/1647422686.png)](https://www.sinovac.com/en-us/news/id-3083 "Latest Real-World Data Show Two-shots of CoronaVac<sup>®</sup> Provides 74.5% Protection Against COVID-19 For Children and Adolescents") Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi - 2022/03/04 #### [Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided](https://www.sinovac.com/en-us/news/id-3082 "Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided") [![Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided](https://www.sinovac.com/upload/thumb_src/800_500/1646402303601397.jpg)](https://www.sinovac.com/en-us/news/id-3082 "Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided") During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p - 2022/02/25 #### [CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony](https://www.sinovac.com/en-us/news/id-3063 "CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony") [![CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony](https://www.sinovac.com/upload/thumb_src/800_500/1647342724.png)](https://www.sinovac.com/en-us/news/id-3063 "CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony") Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C - 2022/02/18 #### [CUHK and SINOVAC join in hands in building P3 laboratory](https://www.sinovac.com/en-us/news/id-3065 "CUHK and SINOVAC join in hands in building P3 laboratory") [![CUHK and SINOVAC join in hands in building P3 laboratory](https://www.sinovac.com/upload/thumb_src/800_500/1647334058.png)](https://www.sinovac.com/en-us/news/id-3065 "CUHK and SINOVAC join in hands in building P3 laboratory") Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework - 2021/12/31 #### [SINOVAC Reports Unaudited First Half of 2021 Financial Results](https://www.sinovac.com/en-us/news/id-3038 "SINOVAC Reports Unaudited First Half of 2021 Financial Results") BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results [Previous page](https://www.sinovac.com/en-us/news/release/page/4)[1\...](https://www.sinovac.com/en-us/news/release)[2](https://www.sinovac.com/en-us/news/release/page/2)[3](https://www.sinovac.com/en-us/news/release/page/3)[4](https://www.sinovac.com/en-us/news/release/page/4)[5](https://www.sinovac.com/en-us/news/release/page/5)[6](https://www.sinovac.com/en-us/news/release/page/6)[7](https://www.sinovac.com/en-us/news/release/page/7)[8](https://www.sinovac.com/en-us/news/release/page/8)[...26](https://www.sinovac.com/en-us/news/release/page/26)[Next page](https://www.sinovac.com/en-us/news/release/page/6) Go to No.
Shard	74 (laksa)
Root Hash	13504451120479472074
Unparsed URL	com,sinovac!www,/en-us/news/release/page/5 s443